Roivant Sciences Ltd. (ROIV) Stock Forecast
ROIV analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.54 / 5 from 13 analysts
- Price target
- $48.27 average of analyst targets
- Upside to target
- +44.0% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-0.52
- 52-week range
- $17.74 – $41.81
ROIV analyst ratings
13 analystsNumber of analysts at each rating.
ROIV price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ROIV earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.45 | −$0.59 | −$0.35 | −$0.28 | −63.3% | 3 |
| Next quarter (Dec '26) | −$0.41 | −$0.53 | −$0.35 | −$0.24 | −72.1% | 3 |
| Current fiscal year (FY2027) | −$1.58 | −$1.96 | −$1.23 | −$1.08 | −46.7% | 3 |
| Next fiscal year (FY2028) | −$1.72 | −$2.10 | −$1.27 | −$1.58 | −8.7% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ROIV revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $3.7M | $0 | $8.0M | +136.1% | 11 |
| Next quarter (Dec '26) | $12.3M | $0 | $27.0M | +515.1% | 11 |
| Current fiscal year (FY2027) | $52.1M | $13.9M | $91.4M | +530.8% | 12 |
| Next fiscal year (FY2028) | $409.5M | $119.0M | $637.3M | +685.9% | 12 |
ROIV EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ROIV revenue: reported and forecast
ROIV EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.40 | −$0.40 | −$0.45 | −$0.45 | −$0.45 | +13.6% | 0 up · 3 down |
| Next quarter (Dec '26) | −$0.36 | −$0.36 | −$0.41 | −$0.41 | −$0.41 | +13.0% | 0 up · 3 down |
| Current fiscal year (FY2027) | −$1.50 | −$1.50 | −$1.58 | −$1.58 | −$1.58 | +5.7% | 0 up · 3 down |
| Next fiscal year (FY2028) | −$1.56 | −$1.56 | −$1.72 | −$1.72 | −$1.72 | +10.2% | 1 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ROIV earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ROIV beat in 8 of 12.
What analysts expect from ROIV
13 analysts cover Roivant Sciences; their consensus rating is strong buy (4.54 on a 1–5 scale, where 5 is a strong buy). The average price target is $48.27, 44.0% above the latest close of $33.53. Analysts expect earnings of −$1.58 per share for FY2027, −46.7% from a year earlier. For FY2028 the average estimate is −$1.72 per share on revenue of $409.5 million. Roivant Sciences beat the EPS estimate in 8 of the last 12 quarters.
Related: ROIV income statement, ROIV key metrics, ROIV chart. See the ROIV stock overview for the latest quote and news.
ROIV forecast FAQ
What is Roivant Sciences's price target?
The average analyst price target for Roivant Sciences is $48.27, 44.0% above the latest close of $33.53.
Is Roivant Sciences a buy, hold or sell?
Of 13 analysts covering Roivant Sciences, 9 rate it a strong buy, 2 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Roivant Sciences's EPS forecast?
Analysts forecast −$1.58 per share for FY2027 (range −$1.96 to −$1.23); for FY2028 the estimate is −$1.72.
What is Roivant Sciences's revenue forecast?
The average revenue estimate for FY2027 is $52.1 million, growth of 530.8%; for FY2028 it is $409.5 million.
When does Roivant Sciences report earnings?
Roivant Sciences is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 before the market opens; the EPS estimate is $-0.52.
Does Roivant Sciences usually beat earnings estimates?
Roivant Sciences reported EPS at or above the analyst estimate in 8 of the last 12 quarters.